Has Ewa Olech received payments from drug or device companies?

Yes. Drug and device makers reported $287,152 in general payments to Ewa Olech across 383 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ewa Olech did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ewa Olech come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ewa Olech

Rheumatology · Las Vegas, NVNPI 1225007032

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $224,395 of the $287,152 with a category attached, or 78.1%. AbbVie accounts for 76.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $98,539 and has fallen 58.2% since, to $41,204 in 2025. Among rheumatology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$287,152in general payments, 2019–2025

Across 383 payments — averaging $749.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$218K
Merck$28K
Pfizer$19K
Amgen$18K
UCB, Inc.$3K
Novartis$682
plus $881 from 6 others

$17,255in research payments, 2019–2025

Across 23 payments — averaging $750.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$10K
GSK$8K

What the payments were for

Consulting fees$19,7407%
Speaking & faculty fees$224,39578%
Travel & lodging$31,26611%
Food & beverage$11,6954%
Education$550%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	262	$218,287
Merck	37	$28,174
Pfizer	23	$18,716
Amgen	36	$17,600
UCB, Inc.	5	$2,813
Novartis	7	$682
Janssen Scientific Affairs, LLC	6	$261
AstraZeneca	2	$242
Genentech, Inc.	1	$129
E.r. Squibb & Sons, L.L.C.	2	$121
Johnson & Johnson	1	$87
GSK	1	$40

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Rinvoq$151,633
Skyrizi$34,501
RENFLEXIS$27,801
XELJANZ$18,445
Enbrel$17,055
Humira$14,600
COSENTYX$470
Otezla$309
Bimzelx$244
SAPHNELO$242
Rituxan$129
EVENITY$120
ORENCIA$118

How this compares

$287,152 in reported general payments places this provider in the 95th percentile of 43 rheumatology providers in Nevada.

See all rheumatology providers in Nevada →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Enbrel SureclickEtanercept	11	$80,769

Paid to pharmacies, not to this prescriber.

Other rheumatology in Las Vegas

Walter ChathamLas Vegas$197K
George KellyLas Vegas$185K
Nasim DaoudLas Vegas$109K
William KimLas Vegas$16K
Aida LoudyiLas Vegas$10K
Tudor JianuLas Vegas$8K
Khalil Ibrahim BourjiLas Vegas$7K
Neil BraunsteinLas Vegas$6K
Michael CliffordLas Vegas$4K
Chen TangLas Vegas$4K

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →